State Street SPDR S&P Biotech ETF
746 hedge funds and large institutions have $8.21B invested in State Street SPDR S&P Biotech ETF in 2022 Q4 according to their latest regulatory filings, with 122 funds opening new positions, 232 increasing their positions, 241 reducing their positions, and 63 closing their positions.
94% more first-time investments, than exits
New positions opened: 122 | Existing positions closed: 63
28% more capital invested
Capital invested by funds: $6.43B → $8.21B (+$1.78B)
27% more call options, than puts
Call options by funds: $1.66B | Put options by funds: $1.31B
6% more funds holding
Funds holding: 704 → 746 (+42)
0.09% more ownership
Funds ownership: 94.77% → 94.86% (+0.09%)
4% less repeat investments, than reductions
Existing positions increased: 232 | Existing positions reduced: 241
6% less funds holding in top 10
Funds holding in top 10: 33 → 31 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
Moore Capital Management
New York
|
+$258M |
| 2 |
Citigroup
New York
|
+$208M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$191M |
| 4 |
APF
Alaska Permanent Fund
Juneau,
Alaska
|
+$148M |
| 5 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
+$89.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$129M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$120M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$111M |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$110M |
| 5 |
Morgan Stanley
New York
|
-$106M |
XBI Hedge Fund Activity: Q4 2022 in Review
746 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q4 2022, worth a combined $8.21B — up 28% from $6.43B a quarter earlier.
Buyers outnumbered sellers: 122 funds opened new XBI positions and 63 closed out — a net gain of 59 holders — while 232 added to existing stakes and 241 trimmed.
The largest buyer was Moore Capital Management, opening a new position worth an estimated $258M. The largest seller was BNP Paribas Financial Markets, cutting an estimated $129M.
- 746 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q4 2022, up from 704 in Q3 2022.
- Funds reported $8.21B of State Street SPDR S&P Biotech ETF stock for Q4 2022, up 28% quarter-over-quarter.
- 122 funds opened new State Street SPDR S&P Biotech ETF positions in Q4 2022 and 63 closed out, a net change of +59 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q4 2022 was Moore Capital Management, an estimated $258M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q4 2022 was BNP Paribas Financial Markets, an estimated $129M sold.
Based on aggregated 13F filings for Q4 2022.